BioWorld

Jan. 4, 2007

Cytokinetics Forms $725M Heart Disease Alliance With Amgen

Providing leverage for a small-molecule program targeted at heart failure, Cytokinetics Inc. is collaborating with Amgen Inc. in a deal potentially worth $725 million. (BioWorld Today) Read More

Genentech Paying Exelixis $40M In MEK Inhibitor Deal

Cloned Cows Safe, Knockouts Healthy, But Not In Supermarket

FivePrime Signs Discovery Deal With Centocor; $15M Up Front

VaxGen Future Unclear With Additional $51M Celltrion Sale

FDA Signs Off On Poniard's Phase III Picoplatin Protocol

Other News To Note

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for July 22, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for July 21, 2026

To viral or not to viral: In vivo CAR T debates delivery tech

BioWorld

The field of cell and gene therapy is moving toward a new phase of scalability and clinical durability, with in vivo chimeric antigen receptor (CAR) T-cell...

Click chemistry drug bound to pancreatic cancer cells from mice

In vivo click ADCs could address tumor heterogeneity

BioWorld

Researchers at Washington University in St. Louis have used click chemistry to link a second antibody to a pre-existing antibody-drug conjugate (ADC) in vivo. In...

Tree in the shape of human head losing leaves

KBN-2201 reverses key features of Alzheimer’s in mice

BioWorld Science

Researchers from Ajou University School of Medicine reported the preclinical efficacy of KBN-2201 in a mouse model of late-stage Alzheimer’s disease.